600056 中国医药
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.9664.9399.3686.982--
总资产报酬率 ROA (%)1.2931.5802.8592.196--
投入资产回报率 ROIC (%)2.0782.5394.7343.594--

边际利润分析
销售毛利率 (%)10.50210.73611.29112.62714.396
营业利润率 (%)2.8932.7994.3073.1912.586
息税前利润/营业总收入 (%)3.1373.4614.5143.5503.206
净利润/营业总收入 (%)1.9082.0823.1992.3631.971

收益指标分析
经营活动净收益/利润总额(%)125.012121.41680.615121.618186.516
价值变动净收益/利润总额(%)-7.0276.288-0.9034.4254.417
营业外收支净额/利润总额(%)-2.3712.139-1.937-0.2990.316

偿债能力分析
流动比率 (X)1.4231.5231.5841.495--
速动比率 (X)1.1161.1741.2381.158--
资产负债率 (%)61.04460.55862.87763.312--
带息债务/全部投入资本 (%)37.48237.75735.64538.609--
股东权益/带息债务 (%)141.545137.049143.241129.484--
股东权益/负债合计 (%)52.58754.68749.14747.581--
利息保障倍数 (X)10.0835.76715.6439.6485.241

营运能力分析
应收账款周转天数 (天)138.467137.172125.141116.4460.000
存货周转天数 (天)70.25671.59064.36664.3380.000